Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: GlobeNewswire
Sanofi delivers strong 2019 business EPS growth of 6.8% at CER Q4 2019 Change Change at CER 2019 Change Change at CER IFRS net sales reported €9,608m +6.8% +4.7% €36,126m +4.8% +2.8% IFRS net income reported -€10m -103.9%(2) - €2,806m -34.8%(2) - IFRS EPS reported -€0.01 -105.0%(2) - €2.24 -35.1%(2) - Business net income(1) €1,684m +23.5% +18.4% €7,489m +9.8% +7.0% Business EPS(1 €1.34 +21.8% +17.3% €5.99 +9.5% +6.8% Fourth-quarter 2019 sales performance(3) driven by Dupixent® and Vaccines Net sales were €9,608 million, up 6.8% on a reported basis and 4.7%(3) at CER.Dupixent® (global sales €679 million, up 135%) the largest growth contributor, drove Sanofi Genzyme GBU sales up 19.7%.Vaccines sales increased 22.0%, reflecting majority of U.S. influenza vaccine shipments in Q4.CHC sales down 5.2%, mainly
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head [Forbes]Forbes
- Measuring Cross-Platform Ad Effectiveness Using A Single-Source [Forbes]Forbes
- Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaGlobeNewswire
- Neuraxpharm reports another year of sustained growth and international expansion [Yahoo! Finance]Yahoo! Finance
- Diabetics left without treatment as global rate of disease doubles [Financial Times (FT.com) (UK)]Financial Times
SNY
Analyst Actions
- 9/19/24 - Citigroup Inc.
SNY
Sec Filings
- 11/7/24 - Form SC
- 11/7/24 - Form 6-K
- 10/31/24 - Form 6-K
- SNY's page on the SEC website